Fiksirovannaya kombinatsiya saksagliptina i metformina modifitsirovannogo vysvobozhdeniya - novyy shag v uluchshenii priverzhennosti k lecheniyu sakharnogo diabeta 2 tipa


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, growing evidence-based data in the field of diabetology indicate that the optimal components for the realization of the concept of modern fixed combination (FC) includes saxagliptin and metformin MR. New FC of saxagliptin and metformin MR, Kombiglyce Prolong, has a high efficiency, good safety and tolerability profile, and convenient to use. These benefits all allow to improve patients’ adherence to the treatment of type 2 diabetes mellitus.

全文:

受限制的访问

作者简介

E. Biryukova

Email: lena@obsudim.ru

参考

  1. Bohannon N. Overview of the gliptin class (Dipeptidyl Peptidase-4 Inhibitors) in clinical practice. Postgraduate Medicine 2009; 121(1): 1-6.
  2. Ho P.M., Rumsfeld J.S., Masoudi F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006; 166: 1836-41.
  3. Rozenfeld Y., Hunt J.S., Plauschinat C., Wong K.S. Oral antidiabetic medication adherence and glycemic control in managed care. Am. J. Manag. Care. 2008; 14: 71-5.
  4. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27: 1218-24.
  5. Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev. 2002; 18(Suppl 3): S32-5.
  6. Melikian C., White T.J., Vanderplas A., Dezii C.M., Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther. 2002; 24(3): 460-67.
  7. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet. Med. 2010; 27(7): 739-43.
  8. Han S., Iglay K., Davies M.J., Zhang Q., Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr. Med. Res. Opin. 2012; 8(6): 969-77.
  9. Инструкция по медицинскому применению лекарственного препарата Комбоглиз Пролонг® c учетом изменений 1-3. Регистрационное удостоверение ЛП-002068 от 14.05.2013.
  10. Мартынов А.А., Спиридонова Е.В., Бутарева М.М. Повышение приверженности пациентов стационаров и амбулаторнополиклинических подразделений к лечебнореабилитационным программам и факторы, оказывающие влияние на комплаентность. Вестник дерматологии и венерологии 2012; 1: 21-27.
  11. Rosenstock J., Sankoh S., List J.F. Glucoselowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes. Metab. 2008; 10(5): 376-86.
  12. Göke B., et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J. Clin. Pract. 2010; 64: 1619-31.
  13. Fujioka K., Pans M., Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extendedrelease formulation. Clin. Ther. 2003; 25: 515-29.
  14. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998; 352: 854-65.
  15. Алгоритмы специализированной медицинской помощи больных сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, 6-й вып., М., 2013.
  16. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. Ann Intern. Med. 2002; 137: 25-33.
  17. He L., Sabet A., Djedjos S., et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 15; 137(4): 635-46.
  18. Инструкция по медицинскому применению лекарственного препарата Глюкофаж Лонг (таблетки, пролонгированного действия, 500 мг). Регистрационное удостоверение ЛСР 002098/10 (изменение № 1) от 08.02.2013.
  19. Gusler G., Gorsline J., Levy G., et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J. Clin. Pharmacol. 2001; 41: 655-61.
  20. Инструкция по медицинскому применению лекарственного препарата Онглиза® с учетом изменений 1-5. Регистрационное удостоверение. № ЛСР-008697/10 от 25.08.10 г.
  21. Drucker D.J. Biological action and therapeutic potenctial of the glucagon-like peptides. Gastroenterology 2002; 122: 531-44.
  22. Ahren B. GLP-1 and extra-islet effects. Horm. Metab. Res. 2004; 36(11-12): 842-45.
  23. Paes A.H.P., Bakker A., Soe-Agnie C.J. Impact of dosage frequency on patient compliance. Diabetes Care. 1997; 20: 1512-7.
  24. Dhillon S., Weber J. Saxagliptin. Drugs. 2009; 69(15): 2103-14.
  25. Boulton D.W., Smith C.H., Li L., et al. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin. Drug Investig. 2011; 31(9): 619-30.
  26. Fonseca V., Zhu T., Karyekar C., Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes. Metab. 2012; 14(4): 365-71.
  27. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649-55.
  28. Jadzinsky M., Pfutzner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab. 2009; 11: 611-22.
  29. Pfutzner A., Paz-Pacheco E., Allen E., et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes. Metab. 2011; 13: 567-76.
  30. Manucci E., Ognibene A., Cremasco F., et al. Effect of metformin on glucagon-like peptide 1(GLP-1) and leptin levels in obese nondiabetic subject. Diabetes Care 2001; 4: 489-94.
  31. Mulherin A.J.1., Oh A.H., Kim H., et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011; 152(12): 4610-19. doi: 10.1210/en.2011-1485. Epub 2011 Oct 4.
  32. Scarpello J.H.B., Howlett H.C.S. Metformin therapy and clinical uses. Vasc. Dis. Res. 2008; 5: 157-67.
  33. Scirica B.M., Bhatt D.L., Braunwald E., et al. The SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N. Engl. J. Med. 2013; 369: 1317-26.
  34. Wolf R., Frederich R., Fiedorek F., et al. Evaluation of CV risk in the saxagliptin clinical trials. Diabetes 2009; 58(Suppl. 1A): 8-LB.
  35. Rao A., et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care. 2008; 31: 1672-78.
  36. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007; 50: 1140-47.
  37. Monami M., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab. Res. Rev. 2006; 22: 477-82.
  38. Center for drug evaluation and research. Clinical pharmacology and biopharmaceutics review(s). Application number: 2006780rig1s000. Kombigliyze XR (FDC); 2010: 108. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200678Orig1s000ClinPharmR.pdf
  39. Timmins P., Donahue S., Meeker J., Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharmacokinet. 2005; 44: 721-29.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##